Spark sets $850,000 price for blindness gene therapy

Jan 04, 2018

Spark Therapeutics announced it will charge $850,000 per patient for its Luxturna breakthrough gene therapy treatment —- a lower price than analysts and investors had predicted.

The FDA approved Luxturna in December, making it the first ever approved a gene therapy for an inherited disease. The treatment promises to help restore sight for patients with a rare genetic condition.

Most had predicted that Spark would charge around $1 million for the one-time treatment. In addition to the price coming in lower than expected, Spark also created a number of payment models to help reduce costs for insurers as well as a performance-based discount program.

Spark’s pricing concessions and performance-based pricing model could potentially make the drug a trendsetter for other gene therapies as they gain approval in a market sensitive to high drug prices.

Read the Reuters coverage


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments